Tango Therapeutics (TNGX) was granted FDA orphan designation for its treatment of malignant glioma, according to a post to the agency’s website.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TNGX:
- 3 Strong Buy-Rated Stocks with a ‘Perfect 10’ Smart Score
- Tango Therapeutics’ Chief Legal Officer Resigns
- Palo Alto upgraded, Li Auto downgraded: Wall Street’s top analyst calls
- Piper starts Tango Therapeutics with an Overweight on TNG462 potential
- Tango Therapeutics initiated with an Overweight at Piper Sandler